Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Volibris (ambrisentan) - Important Safety Information from GlaxoSmithKline as approved by the Irish Medicines Board
Notice type:
3rd Party Publications
Date:
24/07/2012
Problem Or Issue:
Important Safety Information from GlaxoSmithKline, Volibirs (ambrisentan) must not be used in patients with Idiopathic Pulmonary Fibrosis (IPF).
Important safety information - Volibiris (ambrisentan)
« Back
Date Printed: 15/05/2024